

Chapter 80

A β Monomer, Oligomer and Fibril in Alzheimer's Disease

Hiroshi Mori

Osaka City University Medical School, Japan

ABSTRACT

*Alzheimer's disease (AD), the most prevalent disease of aged people, is a progressive neurodegenerative disorder with dementia. Amyloid- β (also known as β -protein and referred to here as A β) is a well-established, seminal peptide in AD that is produced from the amyloid precursor protein (APP) by consecutive digestion with the β secretase of BACE (beta-site amyloid cleaving enzyme) and gamma secretase of the presenilin complex. Abnormal cerebral accumulation of A β in the form of insoluble fibrils in senile plaques and cerebral amyloid angiopathy (CAA) is a neuropathological hallmark of AD. In contrast to insoluble fibrillary A β , a soluble oligomeric complex, ADDL, consists of low-n oligomers of A β , such as A β *56. Despite their different names, it is currently proposed that oligomeric A β is directly involved in synaptic toxicity and cognitive dysfunction in the early stages of AD. This chapter identifies a novel APP mutation (E693delta; referred to as the Osaka mutation) in a pedigree with probable AD, resulting in a variant A β lacking glutamate at position 22. Based on theoretical predictions and in vitro studies on synthetic mutant A β peptides, the mutated A β peptide showed a unique and enhanced oligomerization activity without fibrillization. This was further confirmed by PiB-PET analysis on the proband patient. Collectively, the chapter concludes that the Osaka mutation is the first human evidence for the hypothesis that oligomeric A β is involved in AD.*

INTRODUCTION

Alzheimer's disease (AD) is a well-known, progressive neurodegenerative disorder with dementia. The neuropathological features of AD include senile plaques and neurofibrillary tangles in addition

to cerebral atrophy from massive neuronal loss. Amyloid- β (also known as β -protein and referred to here as A β) is a well-established, seminal peptide in AD that is produced from the amyloid precursor protein (APP) by consecutive digestion with the β -secretase of BACE and gamma-secretase of the presenilin complex. Abnormal cerebral accumulation of A β in the form of insoluble fibrils

DOI: 10.4018/978-1-4666-3604-0.ch080

in senile plaques and cerebral amyloid angiopathy (CAA) is widely believed to cause AD. In contrast to insoluble A β fibrils, a soluble, nonfibrillary oligomeric complex is currently claimed as a new pathological A β species. It has been termed ADDLs (Lambert et al, 1998), low-n oligomer A β , dimer (Walsh et al, 2002), Abeta*56 (Lesne et al, 2006) (here, A β oligomer collectively together). Despite these different names, it has recently been proposed that A β oligomer directly causes synaptic toxicity and cognitive dysfunction in the early stages of AD (Selkoe, 2002). To discuss A β oligomers in depth here, the relationship among ADDLs, A β oligomer, single oligomers of A β (mainly the dimeric form), and A β *56 should be explained. It is not easy to compare one A β oligomer with other morphologically characterized nonfibrillary A β species such as protofibrils (Walsh, Lomakin, Benedek, Condron, & Teplow, 1997), Globulomer (Gellermann et al, 2008), A β O (Kayed et al, 2003), Paranucleus (Bitan, Kirkitadze, Lomakin, Vollers, Benedek & Teplow, 2003), Annulus (Caughey & Lansbury, 2003), amyloidspheroid (Hoshi, 2003), β amyball (Westlind-Danielsson & Arnerup, 2001), (for review in detail, see [Roychaudhuri, Yang, Hoshi & Teplow, 2009]). With these views, new concepts focusing on nonfibrillary and soluble A β complex based on synaptic dysfunction are emerging regarding the cause of AD. Here, I review and discuss the A β oligomer, particularly based on our current knowledge of patients with early onset familial AD as the sole human evidence in support of the so-called "oligomer hypothesis" and its importance to advancing the research of AD etiology.

A FAMILIAL CASE WITH THE EARLY ONSET ALZHEIMER'S DISEASE

The Osaka Mutation of Amyloid Precursor Protein

The proband was a 62-year-old woman with a history of suspected familial AD. She noticed

memory disturbance at the age of 56, and she had no history or symptoms of other neurological disorders. Her Hachinski's ischemic and Mini Mental State Examination (MMSE) scores were normal. MRI and PET scans showed no cortical atrophy or abnormal metabolism, while SPECT demonstrated bilateral mild hypoperfusion in the temporal lobes. An electroencephalogram showed bilateral, intermittent, generalized slow theta activity. Thus, she was diagnosed as having mild cognitive impairment at that time. At the age of 59, she showed ideomotor apraxia, and her MMSE score was 22/30 points. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) and the criteria of the National Institute of Neurological and Communicative Disorders and Stroke, AD and Related Disorders Association (NINCDS-ADRDA), she was diagnosed as having AD. At the age of 62, her MMSE score dropped to 5, and she exhibited cerebellar ataxia. The axial T1-weighted MRI images showed only mild parietal lobe atrophy. Genetic analysis was performed after an appropriate consultation, at which the caregiver gave informed consent to participate in this study. This study was approved by the institutional ethics committee of Osaka City University Graduate School of Medicine. Exons 16 and 17 of APP and all exons of presenilins-1 and -2 were amplified from the patient's genomic DNA by PCR. The DNA sequence of each product was analyzed using a BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Tokyo, Japan) and an ABI PRISM 310 genetic analyzer (Applied Biosystems). Because this patient was found to have a mutation in exon 17 of the APP but not in the exons 1 or 2 of presenilin, only APP exon 17 was examined from other family members. Apolipoprotein E (ApoE) genotyping was performed by detection of the restriction site polymorphism, as described previously (Gellermann et al, 2008).

From the patient and her family members, we identified a novel mutation (hereafter referred to as the Osaka mutation) in APP exon 17. This muta-

5 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

www.igi-global.com/chapter/monomer-oligomer-fibril-alzheimer-disease/76133

Related Content

Mining Medical Data to Develop Clinical Decision Making Tools in Hemodialysis: Prediction of Cardiovascular Events and Feature Selection using a Random Forest Approach

Jasmine Ion Titapiccolo, Manuela Ferrario, Sergio Cerutti, Carlo Barbieri, Flavio Mari, Emanuele Gatti and Maria G. Signorini (2011). *International Journal of Knowledge Discovery in Bioinformatics* (pp. 1-17).

www.irma-international.org/article/mining-medical-data-develop-clinical/73908

Introduction to Holonomic-Compatible Models for Vision

Mitja Perušand Chu Kiong Loo (2011). *Biological and Quantum Computing for Human Vision: Holonomic Models and Applications* (pp. 1-18).

www.irma-international.org/chapter/introduction-holonomic-compatible-models-vision/50500

Impact of Swarm Intelligence Techniques in Diabetes Disease Risk Prediction

Sushruta Mishra, Brojo Kishore Mishra, Soumya Sahoo and Bijayalaxmi Panda (2016). *International Journal of Knowledge Discovery in Bioinformatics* (pp. 29-43).

www.irma-international.org/article/impact-of-swarm-intelligence-techniques-in-diabetes-disease-risk-prediction/172004

Proteomics in Personalized Medicine: An Evolution Not a Revolution

Srijan Goswami (2018). *Applying Big Data Analytics in Bioinformatics and Medicine* (pp. 80-98).

www.irma-international.org/chapter/proteomics-in-personalized-medicine/182942

Pharmacy Data Integrity for Optimal Analytics

C. David Butler (2014). *International Journal of Knowledge Discovery in Bioinformatics* (pp. 21-45).

www.irma-international.org/article/pharmacy-data-integrity-for-optimal-analytics/147302